Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells

Anticancer Research

Volumn 32, Issue 1, 2012, Pages 61-71

  Samuel, Temesgen ^a   Fadlalla, Khalda ^a   Mosley, Lachundra ^a   Katkoori, Venkat ^b   Turner, Timothy ^a   Manne, Upender ^b  

^a TUSKEGEE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

5 FU; Cancer therapy; Colorectal cancer; DNA damaging drugs; Drug diet interaction; Polyphenol; Prostate cancer; Quercetin

Indexed keywords

CAMPTOTHECIN; CYCLIN B1; ETOPOSIDE; FLUOROURACIL; PROTEIN BAX; PROTEIN P21; PROTEIN P53; QUERCETIN; SURVIVIN;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL CYCLE; CELL INTERACTION; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG MEGADOSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN B1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DRUG SYNERGISM; ETOPOSIDE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; PROSTATIC NEOPLASMS; QUERCETIN; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855656085     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. He X and Liu RH: Phytochemicals of apple peels: isolation, structure elucidation, and their antiproliferative and antioxidant activities. J Agric Food Chem 56: 9905-9910, 2008.
2. Boots AW, Haenen GR and Bast A: Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585: 325-337, 2008.
3. de Groot H and Rauen U: Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fundam Clin Pharmacol 12: 249-255, 1998.
4. Terao J: Dietary flavonoids as antioxidants. Forum Nutr 61: 87-94, 2009.
5. Hu P, Wang M, Chen WH, Liu J, Chen L, Yin ST, Yong W, Chen JT, Wang HL and Ruan DY: Quercetin relieves chronic lead exposure-induced impairment of synaptic plasticity in rat dentate gyrus in vivo. Naunyn Schmiedebergs Arch Pharmacol 378: 43-51, 2008.
6. Kelsey NA, Wilkins HM and Linseman DA: Nutraceutical antioxidants as novel neuroprotective agents. Molecules 15: 7792-7814, 2010.
7. Kumar A, Sehgal N, Kumar P, Padi SS and Naidu PS: Protective effect of quercetin against ICV colchicine-induced cognitive dysfunctions and oxidative damage in rats. Phytother Res 22: 1563-1569, 2008.
8. Ossola B, Kaariainen TM and Mannisto PT: The multiple faces of quercetin in neuroprotection. Expert Opin Drug Saf 8: 397-409, 2009.
9. Murphy EA, Davis JM, McClellan JL and Carmichael MD: Quercetin's Effects on Intestinal Polyp Multiplicity and Macrophage Number in the Apc(Min/+) Mouse. Nutr Cancer 63: 421-426, 2011.
10. Vargas AJ and Burd R: Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev 68: 418-428, 2010.
11. Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH and Huynh H: Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol 24: 1297-1304, 2004.
12. Dihal AA, de Boer VC, van der Woude H, Tilburgs C, Bruijntjes JP, Alink GM, Rietjens IM, Woutersen RA and Stierum RH: Quercetin, but not its glycosidated conjugate rutin, inhibits azoxymethane-induced colorectal carcinogenesis in F344 rats. J Nutr 136: 2862-2867, 2006. (Pubitemid 44771787)
13. Araujo JR, Goncalves P and Martel F: Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr Res 31: 77-87, 2011.
14. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM and Lines TC: A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45: 2179-2205, 2007. (Pubitemid 47451573)
15. Du G, Lin H, Yang Y, Zhang S, Wu X, Wang M, Ji L, Lu L, Yu L and Han G: Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol 10: 819-826, 2010.
16. Kuhar M, Sen S and Singh N: Role of mitochondria in quercetin-enhanced chemotherapeutic response in human non-small cell lung carcinoma H-520 cells. Anticancer Res 26: 1297-1303, 2006.
17. Sharma H, Sen S and Singh N: Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 4: 949-955, 2005. (Pubitemid 41598589)
18. Siegelin MD, Reuss DE, Habel A, Rami A and von Deimling A: Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol 11: 122-131, 2009.
19. Staedler D, Idrizi E, Kenzaoui BH and Juillerat-Jeanneret L: Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer chemotherapy and pharmacology 68: 1161-1172, 2011.
20. Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG, Petasis NA, Chen TC and Schonthal AH: Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 113: 5927-5937, 2009.
21. Liu FT, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, Gribben JG, Newland AC and Jia L: Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 112: 3835-3846, 2008.
22. Samuel T, Fadlalla K, Turner T and Yehualaeshet TE: The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle. Nutr Cancer 62: 1025-1035, 2010.
23. Silverstein RA, de Valdivia EG and Visa N: The incorporation of 5-fluorouracil into RNA affects the ribonucleolytic activity of the exosome subunit Rrp6. Mol Cancer Res 9: 332-340, 2011.
24. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
25. Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, van der Heijden MS, Winter JM, Wikiewicz AK, Yeo CJ and Kern SE: Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res 69: 984-991, 2009.
26. Gravalos C, Garcia-Escobar I, Garcia-Alfonso P, Cassinello J, Malon D and Carrato A: Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin Transi Oncol 11: 526-533, 2009.
27. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319, 2006.
28. Fadlalla K, Watson A, Yehualaeshet T, Turner T and Samuel T: Ruta graveolens extract induces DNA damage pathways and blocks Akt activation to inhibit cancer cell proliferation and survival. Anticancer Res 31: 233-241, 2011.
29. Longley DB, Latif T, Boyer J, Allen WL, Maxwell PJ and Johnston PG: The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. Semin Oncol 30: 3-9, 2003. (Pubitemid 36712853)
30. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997. (Pubitemid 27353455)
31. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S and Kurzrock R: Prevalence of complementary medicine use in a phase 1 clinical trials program: The MD Anderson Cancer Center Experience. Cancer 117: 5142-5150, 2011.
32. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA and Adjei AA: Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 22: 4810-4815, 2004.
33. Hlubocky FJ, Ratain MJ, Wen M and Daugherty CK: Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25: 548-554, 2007. (Pubitemid 350002962)
34. Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D and Haines-Kamka T: Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18: 2515-2521, 2000. (Pubitemid 30432516)
35. Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, Steinberg SM and Wootton J: Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 27: 623-630, 2000.
36. Sharma A, Upadhyay AK and Bhat MK: Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells. Cancer Biol Ther 8: 2106-2113, 2009.
37. Xavier CP, Lima CF, Rohde M and Pereira-Wilson C: Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer chemotherapy and pharmacology 68: 1449-1457, 2011.
38. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB and Johnston PG: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10: 2158-2167, 2004. (Pubitemid 38375578)
39. Debes A, Oerding M, Willers R, Gobel U and Wessalowski R: Sensitization of human Ewing's tumor cells to chemotherapy and heat treatment by the bioflavonoid quercetin. Anticancer Res 23: 3359-3366, 2003. (Pubitemid 36975436)
40. Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G and Simon MM: Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br J Cancer 74: 172-177, 1996. (Pubitemid 26254126)
41. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA and O'Connor OA: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68: 8031-8038, 2008.
42. Ramos S: Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52: 507-526, 2008.